To Demonstrate the Relative Bioavailability Study of Ramipril 10 mg Capsules Under Non-Fasting Conditions
Phase 1
Completed
- Conditions
- Hypertension
- Interventions
- Registration Number
- NCT00946621
- Lead Sponsor
- Sandoz
- Brief Summary
To demonstrate the relative bioavailability study of Ramipril 10 mg capsules under non-fasting conditions.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 48
Inclusion Criteria
- No clinically significant abnormal finding on physical exam, medical history, or clinical laboratory results on screening.
Exclusion Criteria
- Positive test results for HIV or hepatitis B or C.
- Treatment for drug or alcohol dependence.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Arm && Interventions
Group Intervention Description 1 Ramipril 10 mg Capsule (Sandoz) Ramipril 10 mg Capsule (Sandoz) 2 Altace (Ramipril) 10 mg Capsule (Aventis Pharmaceutical) Altace (Ramipril) 10 mg Capsule (Aventis Pharmaceutical)
- Primary Outcome Measures
Name Time Method Bioequivalence based on AUC and Cmax 30 days
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What are the molecular mechanisms by which ramipril inhibits angiotensin-converting enzyme (ACE) in hypertension management?
How does the bioavailability of Sandoz ramipril 10 mg compare to Aventis Altace in non-fasting hypertensive patients?
Which biomarkers correlate with ACE inhibitor response in patients with essential hypertension?
What adverse events are associated with ramipril 10 mg capsules in phase 1 trials for primary hypertension?
Are there combination therapies involving ramipril and ARBs that improve blood pressure control in resistant hypertension?